A phase I study of carboplatin and etoposide administered in conjunction with dipyridamole, prochlorperazine and cyclosporine A

Cancer Chemotherapy and Pharmacology

Volumn 46, Issue 5, 2000, Pages 403-410

  Raschko, James W ^a   Synold, Timothy W ^a   Chow, Warren ^a   Coluzzi, Paul ^a   Hamasaki, Victor ^a   Leong, Lucille A ^a   Margolin, Kim A ^a   Morgan, Robert J ^a   Shibata, Stephen I ^a   Somlo, George ^a   Tetef, Merry L ^a   Yen, Yun ^a   Ter Veer, Anna ^a   Doroshow, James H ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

Carboplatin; Drug resistance; Etoposide; Modulation

Indexed keywords

CARBOPLATIN; CYCLOSPORIN A; DIPYRIDAMOLE; ETOPOSIDE; PROCHLORPERAZINE;

ADENOCARCINOMA; ADULT; AGED; ARTICLE; BREAST CARCINOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; FEMALE; GASTROINTESTINAL TUMOR; HEADACHE; HUMAN; HYPOTENSION; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; NAUSEA; NEPHROTOXICITY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SURVIVAL TIME; VOMITING;

EID: 0033738318     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800000142     Document Type: Article

References (39)

1. Atomic absorption spectrophotometry of free circulating platinum species in plasma derived from cis-dichlorodiammineplatinum(II)
2. A program package for simulation and parameter estimation in pharmacokinetic systems
3. High-performance liquid chromatographic method for the determination of etoposide in plasma using electrochemical detection
4. Plasma prochlorperazine assay by high performance liquid chromatography-electrochemistry
5. Role of the calmodulin inhibitor trifluoperazine on the induction and expression of cell cycle traverse perturbations and cytotoxicity of daunorubicin and doxorubicin (Adriamycin) in doxorubicin-resistant P388 mouse leukemia cells
6. Calmodulin: A potential target for cancer chemotherapeutic agents
7. Synergistic inhibitory effects of dipyridamole and vincristine on the growth of human leukaemia and lymphoma cell lines
8. Biochemical modulation Of cisplatin by dipyridamole
9. Dipyridamole enhancement of etoposide sensitivity
10. Phase I and pharmacokinetic trial of intraperitoneal etoposide in combination with the multidrug-resistance-modulating agent dipyridamole
11. Synergism between dipyridamole and cisplatin in human ovarian carcinoma cells in vitro
12. Cyclosporine A suppresses cisplatin-induced c-fos gene expression in ovarian carcinoma cells
13. Cellular events involved in the sensitization of etoposide-resistant cells by inhibitors of calcium-calmodulin-dependent processes. Role of effects of apoptosis, DNA cleavable complex, and phosphorylation
14. The effects of verapamil on the pharmacokinetics of adriamycin
15. Establishment of a cisplatin-resistant human ovarian cancer cell line
16. Treatment of advanced gastric cancer with 5-fluorouracil and cisplatin in combination with dipyridamole
17. Flow cytometric studies on modulation of Cellular adriamycin retention by phenothiazines
18. Modulation of excision repair cross complementation group 1 (ERCC-1) mRNA expression by pharmacological agents in human ovarian carcinoma cells
19. Alteration of etoposide pharmacokinetics and pharmacodynamics by cyclosporine in a phase I trial to modulate multidrug resistance
20. Drug resistance of cancer cells probed
21. Clinical modulation of doxorubicin resistance by the calmodulin-inhibitor, trifluoperazine: A phase I/II trial
22. Phase I trial of carboplatin and infusional cyclosporine in advanced malignancy
23. Enhancement of etoposide-induced cytotoxicity by cyclosporine A
24. Multiple-drug resistance in human cancer
25. Potentiation of cisplatin cytotoxicity in human ovarian carcinoma cell lines by trifluoperazine, a calmodulin inhibitor
26. Restoration of doxorubicin responsiveness in doxorubicin-resistant P388 murine leukemia cells
27. Phase I trial of 5-ftuorouracil and dipyridamole administered by seventy-two-hour concurrent continuous infusion
28. High-performance liquid chromatographic determination of dipyridamole
29. The effects of cyclosporine on the pharmacokinetics of doxorubicin in patients with small cell lung cancer
30. In vivo resistance towards anthracyclines, etoposide, and cis-diamminedichloroplatinum(II)
31. Phase I and pharmacokinetics studies of prochlorperazine 2-h i.v. infusion as a doxorubicin-efflux blocker
32. Non-chemotherapeutic agents that potentiate chemotherapy efficacy
33. Pilot study of multiple chemotherapy resistance modulators plus epirubicin in the treatment of resistant malignancies
34. Dipyridamole binding to proteins in human plasma and tissue culture media
35. Evaluation of formulas using the serum creatinine level to calculate the optimal dosage of carboplatin
36. Correction of altered plasma membrane potentials: A possible mechanism of cyclosporine A and verapamil reversal of pleiotropic drug resistance in neopiasia
37. Methotrexate and dipyridamole combination chemotherapy based upon inhibition of nucleoside salvage in humans
38. High-performance liquid chromatographic analysis of dipyridamole in plasma and whole blood
39. Phase I trial of etoposide with cyclosporin as a modulator of multidrug resistance